Genome sequencing may be the future of the health care system. It can also show the future of an individual’s health, indicating that his genetics, as well as his or her lifestyle, may have predisposed him to certain diseases. There will be a few blood tests and a thorough study of the person’s genetic make-up. The results will then show if they have strong risks in developing certain types of cancer or heart illnesses. Sometimes, an indicator for a very rare but life-threatening condition can also crop up.
The “cancer gene”
It sounds like a cross between E.R. and Star Trek. But the science for genome sequencing is being developed and might become more accessible as time goes by. The benefits can be enormous and be empowering for those who have gone through the tests. Genes without any predisposition for the big C can make their owner rest easy.
On the other hand, those who had inherited the “cancer gene” from their parents do not necessarily have to live out the rest of their days in fear and anxiety. Following the test, they can take steps to reduce their risks and prevent the disease from happening to them.
Is it accessible?
The question remains then: assuming all this is made accessible to the public, how much will they have to pay for it? According to Wired, genome sequencing will add $350 to the overall health costs that the American patient pays for every year. This is a hypothetical statement made by medical researchers who had conducted a genome sequencing experiment on 50 volunteers. The service is not yet available and the $350 is simply projected expense.
The amount is much higher in Australia. Genome sequencing is already being offered by health centers to patients who do want to find out if they are at risk for cancer, a heart attack, or little-known but deadly illnesses.
According to the Sydney Morning Herald, the price for the genome sequencing, along with the resultant consultation, is A$6,400 or US$4,867. The Sydney-based Garvan Institute’s Genome.One launched the service last week and called it a milestone in preventive medicine. Its tests will show patients if they carry genes that make them prone to heart illnesses or the Big C. Another benefit of the Genome.One genome sequencing is that it will also show a patient how they will respond to about 20 known medications. As a result, the doctor can be better informed on the pharmaceutical drugs fit for prescription.
The long-term benefits of genome sequencing are inarguable. People can save thousands of dollars in medical bills, not to mention the stress and anxiety, if they were to find out the conditions they are prone to, and take steps to prevent their development. But $6,400 per test is still a steep price for a lot of patients. Even doctors want the costs down. When a group of physicians was asked their willingness to recommend genome sequencing to their patients, they said they would do so only if the service costs $100.
(Featured image by DepositPhotos)
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [Esperio Partners Review]
This week, we're here to tell you why affiliate marketing is the meaning of life. And no, that's not a...
Binance: Problems with Paysafe and SEPA – Customers Should Exchange Euro for Tether
It is known that Binance has problems with regulators in several European countries, including Germany. But the fact that support...
Qualitime Plans to Reach a Turnover of €11 Million in 2026
At the moment, Qualitime application has 1,800 registered visitors from the main laboratories in the country and about 400 health...
Peruvian Mining Companies Urged to Focus on Redouble ESG Certification Efforts
Experts recently said that the ESG certification of mining companies with operations in Peru will become increasingly important. They also...
Safeguarding Your Business Funds in Periods of Economic Uncertainty
The dust hasn’t yet settled from the 2023 banking crisis, and another closure could very well be right around the...
Cannabis1 week ago
The Netherlands to Launch Cannabis Legalization Pilot Program in December 2023
Biotech4 days ago
PharmaMar Increases Investment in R&D for Oncology by 23%
Cannabis2 weeks ago
CSC Bolzano – the Most Demanding CSC in the German-Speaking Area
Impact Investing2 days ago
Audax, a Low-Risk ESG Company According to Morningstar Sustainalytics ESG Rating